Sarepta Therapeutics,, Inc. (SRPT)
Health Care ยท Pharmaceutical Preparations
Sarepta Therapeutics,, Inc. (SRPT) is listed on Nasdaq, where its shares have traded since June 4, 1997. SentiSense covers Sarepta Therapeutics,, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. The company reports 835 employees, and its corporate website is www.sarepta.com.
About Sarepta Therapeutics,, Inc.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Latest reported results
Sarepta Therapeutics,, Inc. reported revenue of $401.3 million for Q2 FY2026, down 34.3% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 314 institutions reported holding SRPT, with 107.5 million shares worth $1.9 billion in aggregate. The largest reported holders were BlackRock, Vanguard and State Street. Of the 5 largest reported holders, all 5 added shares during the quarter.
More on SRPT
- SRPT sentiment: whether news and social coverage of Sarepta Therapeutics,, Inc. leans bullish or bearish, and the stories driving it.
- SRPT ownership: all 314 reporting institutions, plus insider and congressional trades.
- SRPT financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.
SentiSense also tracks daily options readings for Sarepta Therapeutics,, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Sarepta Therapeutics,, Inc. do?
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders.
What sector is SRPT in?
SentiSense classifies Sarepta Therapeutics,, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does SRPT stock trade?
Sarepta Therapeutics,, Inc. (SRPT) is listed on Nasdaq, where its shares have traded since June 4, 1997.
How many institutions own SRPT?
314 institutions reported a position in SRPT in 13F filings for the quarter ended June 30, 2026, worth $1.9 billion in total.